Hybridoma cell strain capable of generating bacillus cereus non-hemolytic enterotoxin monoclonal antibody and application of hybridoma cell strain
By developing hybridoma cell lines and diabodyne sandwich method for non-hemolytic enterotoxin NheA monoclonal antibody of Bacillus cereus, the problem of time-consuming and professional technology-dependent detection of Bacillus cereus in the prior art was solved, and the rapid Efficient and low-cost detection, suitable for field applications and has high sensitivity and specificity.
Patent Information
- Application Number
- CN202410857822.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
When detecting Bacillus cereus or its toxins, traditional methods take a long time and rely on professional technology. Molecular biological methods are not suitable for on-site detection and have high antibody quality requirements, making it difficult to meet the detection needs of real-time and high sensitivity.
Develop hybridoma cell lines that produce Bacillus cereus non-hemolytic enterotoxin NheA monoclonal antibody and their applications, and use the dual-antibody sandwich method to establish a fast and efficient detection method, using high affinity and high specificity monoclonal antibody KET and SFD was used to detect Bacillus cereus non-hemolytic enterotoxin NheA.
It realizes rapid, simple and low-cost detection of Bacillus cereus non-hemolytic enterotoxin NheA, which is suitable for on-site applications, has high sensitivity and specificity, and is suitable for the detection of dairy samples and disease monitoring.
Smart Images

Figure CN118956772A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical fields of immunology and in vitro diagnosis, in particular to a hybridoma cell strain producing monoclonal antibody of non-hemolytic enterotoxin of Bacillus cereus and application thereof. Background Art
[0002] Bacillus cereus is a Gram-positive bacterium that can produce spores and is widely present in the human environment. Bacillus cereus is considered a conditional pathogen that can cause endophthalmitis, sepsis, etc., and the food poisoning caused by it is the most common and important. Bacillus cereus can produce a variety of toxins that cause diarrhea or vomiting. The toxins that cause diarrhea include monomeric protein cytotoxin K, hemolytic enterotoxin (HBL), and non-hemolytic enterotoxin (Nhe); Nhe is composed of three subunits of non-hemolytic toxins, namely NheA (41.0 kDa), Nhe B (41.0 kDa), and NheC (41.0 kDa).
[0003] At present, the common methods for detecting Bacillus cereus or toxins include traditional biochemical culture methods, molecular biology detection methods, and immunological methods. Among them, the traditional bacterial detection method is to identify through its biological characteristics, mainly including bacterial culture, separation and purification, colony morphology observation, Gram staining microscopy, biochemical identification and biochemical typing. These steps are time-consuming and cumbersome; common molecular biology detection methods include PCR, multiplex PCR, real-time fluorescence quantitative PCR, loop-mediated isothermal amplification technology, recombinase polymerase amplification technology, etc.; and the detection methods based on molecular biology methods usually require professional technicians or are highly dependent on instruments, which are not suitable for on-site detection; antigen-antibody specific reactions have significant advantages in real-time on-site detection, but the accuracy and sensitivity of the detection have high requirements on the quality of antibodies, so it is necessary to prepare antibodies with high specificity and sensitivity to meet the detection needs. Summary of the invention
[0004] In order to solve the above problems existing in the prior art, the present invention provides a hybridoma cell line producing monoclonal antibodies to non-hemolytic enterotoxin of Bacillus cereus and its application, and specifically relates to a hybridoma cell line producing monoclonal antibodies to non-hemolytic enterotoxin NheA of Bacillus cereus, antibodies, kits and their application.
[0005] The present invention is achieved through the following technical solutions:
[0006] The first object of the present invention is to provide a pair of hybridoma cell lines that produce monoclonal antibodies to non-hemolytic enterotoxin Nhe A of Bacillus cereus, including a pair of hybridoma cell lines that have been deposited in the General Microbiology Center of China National Committee for the Preservation of Microorganisms on April 18, 2024, with a deposit address of No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and a deposit number of CGMCC No. 45910;
[0007] And it was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on April 18, 2024, with the deposit address at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No.45911.
[0008] The second object of the present invention is to provide a monoclonal antibody against non-hemolytic enterotoxin Nhe A of Bacillus cereus, which is secreted and produced by the hybridoma cell line.
[0009] Preferably, the Bacillus cereus non-hemolytic enterotoxin NheA monoclonal antibody is produced by the hybridoma cell line KET, and its name is monoclonal antibody KET; and / or, the Bacillus cereus non-hemolytic enterotoxin NheA monoclonal antibody is produced by the hybridoma cell line SFD, and its name is monoclonal antibody SFD.
[0010] The antibody subtypes of the monoclonal antibody KET and the monoclonal antibody SFD are both IgG1.
[0011] The third object of the present invention is to provide a composition comprising the monoclonal antibody against the Bacillus cereus non-hemolytic enterotoxin NheA.
[0012] The fourth object of the present invention is to provide a test strip comprising the Bacillus cereus non-hemolytic enterotoxin NheA monoclonal antibody or the composition according to claim 3.
[0013] The fifth object of the present invention is to provide a kit comprising the Bacillus cereus non-hemolytic enterotoxin NheA monoclonal antibody or the composition.
[0014] In one embodiment of the present invention, the kit includes a monoclonal antibody as a labeling antibody and a monoclonal antibody as a coating antibody;
[0015] The monoclonal antibody used as the labeling antibody is secreted by the hybridoma cell line with a deposit number of CGMCC No.45911; and the monoclonal antibody used as the coating antibody is secreted by the hybridoma cell line with a deposit number of CGMCC No.45910.
[0016] Preferably, the monoclonal antibody KET can be coated on a solid phase carrier; the monoclonal antibody KET can be an antibody with a detection label;
[0017] The solid phase carrier can be preferably selected from at least one of an ELISA plate, microspheres, nitrocellulose membrane, glass cellulose membrane or nylon membrane; more preferably, an ELISA plate. The detection label can be preferably selected from at least one of colloidal gold labeling, enzyme labeling, biotin labeling or fluorescein labeling; the enzyme labeling is preferably selected from any one of the following: horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, β-galactosidase, lysozyme and malate dehydrogenase; more preferably, horseradish peroxidase (HRP).
[0018] In one embodiment of the present invention, the kit is selected from an enzyme-linked immunosorbent assay kit, a fluorescent immunoassay kit or a chemiluminescent immunoassay kit.
[0019] In one embodiment of the present invention, the kit is a double antibody sandwich immunoassay kit.
[0020] Preferably, the double antibody sandwich ELISA detection kit for Bacillus cereus non-hemolytic enterotoxin NheA uses the monoclonal antibody KET as the coating antibody and the monoclonal antibody SFD as the detection antibody; more preferably, the detection antibody (monoclonal antibody SFD) is an antibody labeled with horseradish peroxidase. The monoclonal antibody KET coated on the ELISA plate is used to specifically capture the non-hemolytic enterotoxin NheA of Bacillus cereus, and the enzyme-labeled antibody SFD-HRP on the ELISA plate is combined with the captured cholera toxin A subunit. After the substrate is added, it is catalyzed by the HRP enzyme and produces an absorption value at 450nm. The result is determined according to the P / N value, wherein: if the non-hemolytic enterotoxin NheA of Bacillus cereus is captured by the coated antibody KET and combines with the enzyme-labeled antibody SFD-HRP, and catalyzes the substrate to produce an absorption value at 450nm (P / N≥2.1), it is determined to be positive; if the concentration of the non-hemolytic enterotoxin NheA of Bacillus cereus is too low (P / N<2.1), it is determined to be negative.
[0021] Specifically, the double antibody sandwich ELISA detection kit may further include at least one of the following components: a negative control, a positive control, a stop solution, a color development solution, an enzyme-linked plate, a coating solution, a PBS-T buffer, and a PBS;
[0022] in,
[0023] The color developing solution can be TMB;
[0024] The stop solution may be 10% H2SO4;
[0025] The coating solution can be selected as a carbonate coating buffer with a concentration of 0.01-0.05 M (for example, specifically 0.05 M) and a pH of 9.6.
[0026] The sixth object of the present invention is to provide a method for detecting Bacillus cereus non-hemolytic enterotoxin Nhe A, which comprises: using the kit for detection.
[0027] The seventh object of the present invention is to provide the use of the hybridoma cell line, the Bacillus cereus non-hemolytic enterotoxin NheA monoclonal antibody, the composition, the test strip or the kit in detecting preparations containing Bacillus cereus non-hemolytic enterotoxin NheA.
[0028] The above technical solution of the present invention has the following advantages compared with the prior art:
[0029] The present invention provides a hybridoma cell strain producing a monoclonal antibody to a non-hemolytic enterotoxin of Bacillus cereus and its application. The present invention uses monoclonal antibodies KET and SFD with highly uniform physical and chemical properties, good specificity, and mass production. The monoclonal antibodies KET and SFD are both mouse-derived monoclonal antibodies with high affinity and high specificity. The sandwich method established has high sensitivity and low cost, and provides a rapid and efficient analytical means for the detection of the non-hemolytic enterotoxin NheA antigen of Bacillus cereus, laying a foundation for the development of a rapid detection kit.
[0030] This application uses a double antibody sandwich method to detect the protein level of Bacillus cereus non-hemolytic enterotoxin NheA. It has the following advantages:
[0031] 1. No complicated sample processing is required, only dairy products need to be tested. It is easy to operate, short testing time and low cost.
[0032] 2. The prepared antibodies are specific when detecting dairy samples;
[0033] 3. The biological information obtained through dairy product analysis can monitor disease progression and dynamically evaluate treatment effects;
[0034] 4. Provide a basis for the detection and prevention of Bacillus cereus non-hemolytic enterotoxin NheA.
[0035] Deposit of biological materials:
[0036] The hybridoma cell line KET that produces the monoclonal antibody to non-hemolytic enterotoxin of Bacillus cereus has been deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. It is classified and named as a monoclonal cell line, with a deposit date of April 18, 2024, and a deposit number of CGMCC No. 45910.
[0037] The hybridoma cell line SFD that produces monoclonal antibodies to non-hemolytic enterotoxin of Bacillus cereus has been deposited in the General Microbiology Center of China Culture Collection Administration, with the deposit address at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. It is classified and named as monoclonal cell line, the deposit date is April 18, 2024, and the deposit number is CGMCC No.45911. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:
[0039] Figure 1 This is the SDS-PAGE identification diagram of the NheA recombinant protein after expression and purification in the present invention;
[0040] Figure 2 This is the SDS-PAGE identification diagram of the monoclonal antibodies KET and SFD after purification in the present invention;
[0041] Figure 3 This is the ELISA result diagram of the titer detection of the monoclonal antibody KET in the present invention;
[0042] Figure 4 This is the ELISA result diagram of the titer detection of the monoclonal antibody SFD in the present invention;
[0043] Figure 5 It is the detection standard curve of KET-SFD / HRP of the double antibody sandwich method of the present invention;
[0044] Figure 6 This is a graph showing the cross-reaction rate of the monoclonal antibodies of the present invention to common microbial toxins. DETAILED DESCRIPTION
[0045] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0046] The present invention uses Escherichia coli to recombinantly express NheA protein, immunize mice, and finally obtain paired monoclonal antibody hybridoma cell lines KET and SFD with high sensitivity to ctxA through steps such as cell fusion, HAT selective medium culture, and subcloning.
[0047] The raw materials used in the embodiments and comparative examples of the present invention, unless otherwise specified, are disclosed in the prior art, for example, they can be directly purchased or prepared according to the preparation methods disclosed in the prior art.
[0048] In specific implementation,
[0049] The preparation and screening methods of the hybridoma cell lines KET and SFD can be prepared by conventional methods in the art. The specific method may include the following steps:
[0050] 1. Construction of recombinant plasmid
[0051] According to the gene sequence of Bacillus cereus non-hemolytic enterotoxin NheA published in GenBank (the gene sequence of antigen Bacillus cereus non-hemolytic enterotoxin NheA is shown in SEQ ID No. 1) and the amino acid sequence (SEQ ID No. 2), Wuxi Tianlin Biotechnology Co., Ltd. was responsible for optimizing and synthesizing the complete gene pET 28a-NheA, which was then transformed into BL21 competent cells and plated for culture.
[0052] 2. Protein Expression and Purification
[0053] A single colony was selected from the LB plate and inoculated into LB liquid medium containing ampicillin at 37°C overnight. The next day, the bacteria were inoculated into fresh LB liquid medium at a 1% inoculum volume and cultured at 37°C until the logarithmic phase (OD 600 0.6-0.8), then add the inducing agent IPTG, induce culture at low temperature for 16 hours, collect the bacteria, ultrasonically disrupt the bacteria, centrifuge at 4000×g to remove bacterial debris, then centrifuge at 12000×g for 30 minutes to collect the supernatant, use Ni-NTA purification system to purify the target protein NheA, use Ni-NTA purification system to purify the target protein NheA, dialyze with PBS to remove imidazole, determine the concentration with NanoDrop One instrument, and store at -20 to -30°C.
[0054] Furthermore, the ELISA method may adopt a common method in the art, which may specifically include the following steps:
[0055] (I) Preparation of specific monoclonal antibodies: BALB / c mice aged 6 to 8 weeks were immunized with Nhe A protein as an immunogen, and cells with strong positive expression of NheA protein were screened and subcloned after immunization and fusion to obtain hybridoma cell lines KET and SFD, and ascites was further prepared to finally obtain NheA protein specific monoclonal antibodies KET and SFD;
[0056] (ii) Screening paired monoclonal antibodies: purifying the NheA protein-specific monoclonal antibodies obtained in step (i), and labeling them with horseradish peroxidase HRP, and performing sandwich pairing after successful identification and labeling;
[0057] (III) Establishing a NheA protein-specific sandwich ELISA method: using the paired monoclonal antibodies obtained in step (II), using monoclonal antibody KET as a coating antibody and monoclonal antibody SFD as a detection antibody, wherein the detection antibody is labeled with horseradish peroxidase (SFD-HRP); coating the monoclonal antibody KET on an ELISA plate to specifically capture the NheA protein, then the detection antibody, i.e., the enzyme-labeled antibody SFD-HRP, binds to the captured NheA, and after the addition of the substrate (TMB), it is catalyzed by HRP and produces an absorption value at 450 nm, and the result is determined according to the P / N value, wherein: if NheA is captured by the coating antibody KET and binds to the enzyme-labeled antibody SFD-HRP, and catalyzes the substrate to produce an absorption value at 450 nm, if P / N ≥ 2.1, it is determined to be positive; otherwise, it is determined to be negative.
[0058] Furthermore, the specific detection steps may refer to the commonly used methods in the art, and may specifically include the following steps:
[0059] (1) Coating: Coat the ELISA plate with 4 μg / mL monoclonal antibody KET, using 100 μL / well, and incubate at 37°C for 1 to 3 h;
[0060] (2) Washing: Wash the plate three times with PBST, 3 min each time, 200 μL / well, and then spin dry the reaction plate;
[0061] (3) Blocking: Block the wells with CBS containing 0.2% gelatin at a volume of 300 μL / well and incubate at 37°C for 1 to 3 h.
[0062] (4) Washing: same as step (2);
[0063] (5) Sample: NheA protein was diluted in a gradient manner using PBST (for example, it can be diluted in a 3-fold gradient from 300 ng / mL to 0.4 ng / mL, which can be adjusted according to the actual situation). A PBST blank control was set up. 100 μL of sample was added to each well and incubated at 37°C for 0.5 to 2 h.
[0064] (6) Washing: same as step (2);
[0065] (7) Add 2 μg / mL enzyme-labeled antibody SFD-HRP, 100 μL / well, and react at 37°C for 0.5-2 h;
[0066] (8) Washing: Wash the plate four times;
[0067] (9) Color development: Add color development solution at a ratio of TMB to substrate solution of 1:5, 100 μL / well, and develop for 10 to 20 min;
[0068] (10) Stop: add 50 μL / well of stop solution;
[0069] (11) Determination: OD was measured using an ELISA reader 450 .
[0070] Furthermore, the pairing parameters may include: 4 μg / mL coated antibody KET, coating solution is pH 9.6, 0.05M carbonate buffer, standard (including ctxA protein) concentration is 50 ng / mL, standard diluent is pH 7.2, 0.01M PBST, and the concentration of enzyme-labeled antibody SFD-HRP may be 2 μg / mL.
[0071] The culture medium involved in the following examples is as follows:
[0072] LB liquid medium: peptone (2%), yeast extract (1%), sodium chloride (2%);
[0073] HAT medium: 20% fetal bovine serum, 1×HAT, 500 mL RPMI-1640, 0.5% double antibody;
[0074] RPMI-1640 basal medium, purchased from Gibco;
[0075] The solutions involved in the following embodiments are configured as follows:
[0076] Example 1 Preparation of NheA recombinant protein
[0077] 1. Construction of recombinant plasmid
[0078] According to the NheA gene sequence published in GenBank, the gene sequence is shown in SEQ ID No. 1, and the amino acid sequence (SEQ ID No. 2), Wuxi Tianlin Biotechnology Co., Ltd. was responsible for optimizing and synthesizing the complete plasmid pET28a-Nhe A. The plasmid pET28a-NheA was transformed into Escherichia coli BL21 competent cells and spread on LB plates containing kanamycin for culture.
[0079] 2. Protein expression and purification
[0080] A single colony was selected from the LB plate and inoculated into LB liquid medium containing kanamycin at 37°C overnight. The next day, the bacteria were inoculated into fresh LB liquid medium at a 1% inoculum volume and cultured at 37°C until the logarithmic phase (OD 600 =0.6-0.8), then add induction reagent IPTG, induce culture at low temperature for 16h, collect bacteria, ultrasonically disrupt bacteria, centrifuge at 4000xg to remove bacterial debris, then centrifuge at 12000xg for 30min to collect supernatant, and purify target protein NheA using Ni-NTA purification system (refer to Ni-NTA purification system manual). Take the collected solution of gradient elution for SDS-PAGE verification (refer to Figure 1 ), the eluate with the target band was dialyzed against 0.01M PBS to remove imidazole. The concentration was determined using NanoDrop One instrument and stored at -20°C for future use.
[0081] Example 2
[0082] 1. Preparation of specific monoclonal antibodies
[0083] 1. Experimental animals: BALB / c mice aged 6 to 8 weeks were selected for immunization;
[0084] 2. Emulsification: The protein expressed in Example 1 is emulsified with an equal amount of complete or incomplete Freund's adjuvant, and after the emulsification is complete, multiple subcutaneous injections are prepared into mice;
[0085] 3. Immunity:
[0086] Newly purchased BLAB / c mice were randomly divided into groups of 5 mice / cage and raised in an animal barrier environment for 7 to 10 days to adapt to the environment. NheA protein was used as an immunogen and multiple subcutaneous injections were injected into the back of the neck to immunize the mice. For the first immunization, the immunization dose was 100 μg / mouse. An appropriate amount of immunogen was mixed with an equal volume of Freund's complete adjuvant and fully emulsified on a double-channel injection emulsifier to form an oil-in-water emulsion to immunize the mice. Four weeks later, the first booster immunization was carried out, with an immunization dose of 50 μg / mouse. The immunogen was mixed and emulsified with an equal volume of Freund's incomplete adjuvant. After that, booster immunization was carried out every three weeks, with an immunization dose of 50 μg / mouse and Freund's incomplete adjuvant.
[0087] 4. Blood collection: One week after the second booster immunization, blood was collected from the tail vein of mice to obtain antiserum. The titer of antiserum was determined by indirect non-competitive enzyme-linked immunosorbent assay.
[0088] 5. Cell fusion:
[0089] (1) Feeding of myeloma cells SP2 / 0. 10 days before fusion, thaw the frozen SP2 / 0 cells and expand the culture. Take a portion of the SP2 / 0 cells and culture them in HAT medium for 24 hours to observe whether the cells will undergo apoptosis.
[0090] (2) Feeder cell preparation: The day before fusion, feeder cells from healthy Balb / c mice were plated at a cell concentration of 1×10 5 / mL, 100μL per well.
[0091] (3) Preparation of SP2 / 0: Gently blow off the cells and collect them into a centrifuge tube. Record the total volume of the solution. Mix well and take a small amount of cells and dilute appropriately for counting. Preparation of spleen cells: Take out the spleen of the fused mouse, rinse the spleen with 1640 basal medium, and keep the spleen in a moist environment. Grind the spleen, rinse the spleen cells remaining on the needle core and filter with basal medium, collect the grinding liquid, and record the total volume. Take part of the grinding liquid for counting.
[0092] (4) SP2 / 0 cells and spleen cells were mixed in a centrifuge tube at a ratio of 1:5 to 1:10, centrifuged at 1000 rpm / min for 7 min, and the supernatant was discarded. 1 mL of PEG1450 preheated in 37°C water was added, followed by 15 mL of preheated RPMI-1640 basal medium to terminate the reaction, centrifuged at 1000 rpm / min for 7 min, the supernatant was discarded, and HAT complete medium was added to resuspend, 100 μL was added to each well, and the cells were cultured in a cell culture incubator. The fusion results were observed after five days.
[0093] 6. Positive cell screening and cloning
[0094] (1) Observe the cells on the fifth day after fusion and replace the medium in the wells with larger cell clusters. On the third day, take the cell supernatant and transfer it to a plate coated with 50 ng / well antigen for ELISA test. The positive wells need to be replaced with the medium again and tested again the next day. The wells that test positive twice are cloned.
[0095] (2) The positive cells were cloned using the limiting dilution method. Generally, three clonings were performed to obtain the hybridoma cell lines KET and SFD.
[0096] 7. Preparation of Ascites
[0097] (1) 7 to 14 days before the injection of hybridoma cell lines, 1 mL of sterilized paraffin oil was injected intraperitoneally into the inoculated BaLb / c mice.
[0098] (2) Each mouse was intraperitoneally injected with 2×10 5 ~1×10 6 The injection volume is 1 mL. Generally, the abdomen of the mouse will be obviously bulging after 7 to 14 days, and ascites can be extracted when the mouse moves slowly.
[0099] (3) Centrifuge the collected ascites at 4°C and 12,000 rpm / min for 30 min, take the supernatant, and store it in separate devices at -20°C.
[0100] 8. Antibody purification and storage
[0101] The ascites was purified by the caprylic acid-saturated ammonium sulfate method, and the monoclonal antibodies KET and SFD were obtained after dialysis against 0.01M PBS. The concentrations were determined by the micro-ultraviolet method, and then the products were packaged and stored at -20°C.
[0102] 2. Antibody titer determination steps:
[0103] (1) Dilute the NheA protein to 0.1 μg / mL with 0.05 M, pH 9.6 carbonate coating buffer and coat it on a 96-well ELISA plate at 100 μL / well. Incubate in a 37°C incubator for 2 h. Remove the ELISA plate and spin dry it. Inject 200 μL of PBST solution into each well and shake on a shaker for 3 min. Shake off the washing solution vigorously and pat dry on absorbent paper. Wash twice more. The following washing methods are the same.
[0104] (2) After thorough washing, block the ELISA plate with blocking buffer (0.2% gelatin in CBS), 200 μL / well, incubate in a 37°C incubator for 2 h, then remove, wash, and dry for later use;
[0105] (3) Antibodies KET and SFD were serially diluted 10,000, 20,000, 40,000, 80,000, 160,000, 320,000, and 640,000 times, respectively. They were added to the first 7 rows of the ELISA plate, and the diluent was added to the 8th row as a control, 100 μL / well, incubated at 37°C for 35 min, then washed and patted dry;
[0106] (4) Add 100 μL of 1:3000 diluted HRP-labeled goat anti-mouse IgG to each well, incubate at 37°C for 35 min, wash four times, and pat dry;
[0107] (5) Add 100 μL of colorimetric solution (TMB to substrate solution ratio of 1:5) to each well and react at 37°C in the dark for 15 min. After removal, add 50 μL of stop solution (10% sulfuric acid) to each well and measure the absorbance OD using an ELISA reader. 450 (Results such as Figure 3 , Figure 4 ). Figure 3 and Figure 4 It can be seen that the mouse antiserum titer exceeds 320k, meeting the fusion requirement.
[0108] 3. Specific double antibody sandwich assay steps:
[0109] a. Coating: Coat the ELISA plate with 4 μg / mL monoclonal antibody KET, 100 μL / well, incubate at 37°C for 2 h;
[0110] b. Washing: Wash the plate three times with PBST, 3 min each time, 200 μL / well, and then spin dry the reaction plate;
[0111] c. Blocking: CBS containing 0.2% gelatin, 200 μL / well, blocking at 37°C for 2 h;
[0112] d. Washing: Wash the plate three times with PBST, 3 min each time, 200 μL / well, and then spin dry the reaction plate;
[0113] e. Sample: NheA was diluted 3-fold from 300 ng / mL to 0.4 ng / mL (300 ng / mL, 100 ng / mL, 33.33 ng / mL, 11.11 ng / mL, 3.4 ng / mL, 1.2 ng / mL, 0.4 ng / mL) with PBST, and a PBST blank control was set up. 100 μL of sample was added to each well and incubated at 37°C for 1 hour;
[0114] f. Washing: Wash the plate three times with PBST, 3 min each time, 200 μL / well, and then spin dry the reaction plate;
[0115] g. Add enzyme-labeled antibody (SFD-HRP, 2 μg / mL), 100 μL / well, react at 37°C for 1 h;
[0116] h. Washing: Wash the plate four times;
[0117] i. Color development: add 100 μL / well of color development solution (TMB to substrate solution ratio is 1:5) and color development for 12 min;
[0118] j. Stop: add stop solution (10% sulfuric acid), 50 μL / well;
[0119] k. Determination: Detect OD with an enzyme reader 450 value.
[0120] 4. The double antibody sandwich ELISA detection method with monoclonal antibody KET as coating antibody and monoclonal antibody SFD as detection antibody was established. The detection curve and detection range were established: Antibody KET was diluted to 4 μg / mL with 0.05M, pH 9.6 carbonate coating buffer, 100 μL was added to each well, and incubated at 4°C overnight. Washing, CBS containing 0.2% gelatin, 200 μL / well, blocked at 37°C for 2 hours. Washing, adding different concentrations of recombinant Nhe A protein diluted with PBST buffer solution as antigen (300 ng / mL, 100 ng / mL, 33.33 ng / mL, 11.11 ng / mL, 3.4 ng / mL, 1.2 ng / mL, 0.4 ng / mL), 100 μL per well, incubated at 37°C for 1 hour. Washing, adding 100 μL of diluted enzyme-labeled antibody SFD-HRP (2 μg / mL) to each well, incubated at 37°C for 1 hour. Wash, add 100 μL of TMB colorimetric solution to each well, color for 12 minutes, and add 50 μL of stop solution (10% H2SO4). Read the absorbance value OD at 450 nm with an ELISA reader 450 , analyze the data, and make a standard curve based on the data. When the Nhe A concentration is in the range of 0.4 ng / mL to 300 ng / mL, as the Nhe A concentration increases, the ELISA reaction OD 450 The value increased, and the NheA concentration was related to OD 450 The values are linearly correlated, so the detection range of this method is: 0.4ng / mL~300ng / mL, and the detection limit is the antigen concentration when P / N is greater than 2.1, that is, 0.28ng / mL. A standard curve of the double antibody sandwich ELISA detection method with KET as the coating antibody and SFD as the detection antibody was drawn ( Figure 5 ).
[0121] Example 3
[0122] The cross-reactivity rate of monoclonal antibodies to common microbial toxins such as botulinum toxin, Staphylococcus aureus enterotoxin SEA, SEB, SEC, SED, SEE, Bacillus cereus non-hemolytic toxin Nhe C, hemolytic toxin HBLA, HBL2 was determined. Figure 6 As shown; it can be seen that the monoclonal antibody obtained by the present invention has no cross-reaction with microbial toxins such as botulinum toxin, Staphylococcus aureus enterotoxin SEA, SEB, SEC, SED, SEE, Bacillus cereus non-hemolytic toxin Nhe C, hemolytic toxin HBLA, HBL2, indicating that the monoclonal antibody of the present invention has good specificity and the established detection method has high specificity.
[0123] In order to verify the practicality of the detection kit, milk and rice matrices were selected as samples for the addition recovery experiment, as shown in Table 1 below:
[0124] Table 1
[0125]
[0126] As can be seen from Table 1, the paired monoclonal antibody KET-SFD was used for the detection of milk and rice samples, with three concentrations of 100 ng / mL, 50 ng / mL and 5 ng / mL added respectively, and detected by ELISA. The recovery rates were between 84.2% and 108.28%, and the coefficients of variation were all less than 10%.
[0127] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A pair of hybridoma cell lines producing monoclonal antibodies to Bacillus cereus non-hemolytic enterotoxin Nhe A, It is characterized in that Including those deposited in the General Microbiology Center of China Microorganism Culture Collection Committee on April 18, 2024, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 45910; And it was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on April 18, 2024, with the deposit address at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No.45911.
2. A monoclonal antibody against Bacillus cereus non-hemolytic enterotoxin Nhe A, It is characterized in that Produced by secretion from the hybridoma cell line of claim 1.
3. A composition, It is characterized in that It comprises the Bacillus cereus non-hemolytic enterotoxin Nhe A monoclonal antibody as described in claim 2.
4. A test strip, It is characterized in that It comprises the Bacillus cereus non-hemolytic enterotoxin Nhe A monoclonal antibody according to claim 2 or the composition according to claim 3.
5. A kit, It is characterized in that It comprises the Bacillus cereus non-hemolytic enterotoxin Nhe A monoclonal antibody according to claim 2 or the composition according to claim 3.
6. The kit according to claim 5, It is characterized in that Including monoclonal antibodies as labeling antibodies and monoclonal antibodies as coating antibodies; The monoclonal antibody used as the labeling antibody is secreted by the hybridoma cell line with a deposit number of CGMCC No.45911; and the monoclonal antibody used as the coating antibody is secreted by the hybridoma cell line with a deposit number of CGMCC No.45910.
7. The kit according to claim 5, It is characterized in that The kit is selected from an enzyme-linked immunosorbent assay kit, a fluorescent immunoassay kit or a chemiluminescent immunoassay kit.
8. The kit according to claim 5, It is characterized in that The kit is a double antibody sandwich immunoassay kit.
9. A method for detecting non-hemolytic enterotoxin Nhe A of Bacillus cereus, It is characterized in that The detection method comprises: performing detection using the kit described in any one of claims 5 to 8.
10. Use of the hybridoma cell line according to claim 1, the monoclonal antibody against non-hemolytic enterotoxin Nhe A of Bacillus cereus according to claim 2, the composition according to claim 3, the test strip according to claim 4 or the kit according to any one of claims 5 to 8 in detecting a preparation containing non-hemolytic enterotoxin Nhe A of Bacillus cereus.
Citation Information
Patent Citations
Hybridoma cell strain for producing cholera toxin A subunit monoclonal antibody, antibody, kit and application thereof
CN118308307A
A pair of antigen binding proteins specifically binding to bacillus cereus Nhe A
CN118459579A
Determination of the absence or presence of Bacillus cereus enterotoxin via a western blot
US9063034B1
